Tech Company Financing Transactions
Minghui Pharmaceutical Funding Round
Minghui Pharmaceutical, based in Shanghai, secured $131 million from OrbiMed, Qiming Venture Partners USA and 5Y Capital.
Transaction Overview
Company Name
Announced On
8/11/2025
Transaction Type
Venture Equity
Amount
$131,000,000
Round
Undisclosed
Investors
OrbiMed (Lead Investor)
Qiming Venture Partners USA (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its clinical programs, with a particular focus on its PD-1/VEGF bispecific antibody and combination strategies with antibody-drug conjugates (ADCs).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Building 6, 338 Jialilue Road, China (Shanghai) Pilot Free T 6305
Shanghai, Undisclosed
China
Shanghai, Undisclosed
China
Phone
Website
Email Address
Overview
Minghui Pharmaceutical is a global biopharmaceutical company dedicated to developing innovative medicines for the benefit of patients with diseases of largely unmet medical needs. Leveraging our expertise in medical science and the proprietary technology platforms, we are developing a rich clinical-stage pipeline including a variety of first-in-class or best-in-class drug candidates. We are committed to serving patients around the world.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Guoqing Cao
Browse more venture capital transactions:
Prev: 8/11/2025: Aira venture capital transaction
Next: 8/11/2025: Xpand venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record all VC transactions involving tech companies. VC investment data records on this site come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs